Format

Send to

Choose Destination
Int J Nanomedicine. 2012;7:1551-72. doi: 10.2147/IJN.S29997. Epub 2012 Mar 22.

Inhaled chemotherapy in lung cancer: future concept of nanomedicine.

Author information

1
Pulmonary Department, G Papanikolaou General Hospital, Aristotle University of Thessaloniki, Greece. pzarog@hotmail.com

Abstract

Regional chemotherapy was first used for lung cancer 30 years ago. Since then, new methods of drug delivery and pharmaceuticals have been investigated in vitro, and in animals and humans. An extensive review of drug delivery systems, pharmaceuticals, patient monitoring, methods of enhancing inhaled drug deposition, safety and efficacy, and also additional applications of inhaled chemotherapy and its advantages and disadvantages are presented. Regional chemotherapy to the lung parenchyma for lung cancer is feasible and efficient. Safety depends on the chemotherapy agent delivered to the lungs and is dose-dependent and time-dependent. Further evaluation is needed to provide data regarding early lung cancer stages, and whether regional chemotherapy can be used as neoadjuvant or adjuvant treatment. Finally, inhaled chemotherapy could one day be administered at home with fewer systemic adverse effects.

KEYWORDS:

carriers; inhaled chemotherapy; transducers

PMID:
22619512
PMCID:
PMC3356182
DOI:
10.2147/IJN.S29997
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center